Vancomycin‐resistant Enterococcus bacteremia: An evaluation of treatment with linezolid or daptomycin
Journal of Hospital Medicine2011Vol. 7(3), pp. 243–248
Citations Over TimeTop 10% of 2011 papers
Jennifer D. Twilla, Christopher K. Finch, Justin B. Usery, Mikhail S. Gelfand, Joanna Q. Hudson, Joyce E. Broyles
Abstract
No differences in clinical or microbiologic cure rates, LOS, or mortality were identified between the groups. Various factors may have contributed to the significantly higher recurrence of VRE bacteremia in daptomycin patients. This study suggests that linezolid and daptomycin appear equally efficacious in the treatment of VRE bacteremia.
Related Papers
- → Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute(2019)62 cited
- → The first linezolid-resistant Enterococcus faecium in India: High level resistance in a patient with no previous antibiotic exposure(2014)25 cited
- → Emergence of linezolid-resistant Enterococcus faecium during treatment of enterococcal infections(2003)24 cited
- → Daptomycin susceptibility testing and therapeutic use in enterococcal bloodstream infection (EBSI) in a setting with high rates of vancomycin-resistant Enterococcus faecium (VREfm)(2022)3 cited
- → Evaluation of the antimicrobial activity of daptomycin and linezolid against vancomycin-resistant Enterococcus spp. isolates in south India(2014)2 cited